Previous studies have shown that CD38-knockout mice exhibit higher NAD+ levels and reduced metabolic syndrome in obesity [103], and CD38 inhibitors elevate cellular NAD+ levels and improve various aspects of both glucose and lipid homeostasis [104]. The gene discussed is CD38; the disease is metabolic syndrome.